These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 36263027

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS, Chackerian B.
    Vaccine; 2015 Jun 26; 33(29):3346-53. PubMed ID: 26003490
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.
    Vaccine; 2007 Mar 01; 25(11):2001-10. PubMed ID: 17239496
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.
    Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H.
    Vaccine; 2012 May 09; 30(22):3286-94. PubMed ID: 22426329
    [Abstract] [Full Text] [Related]

  • 27. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.
    PLoS One; 2014 May 09; 9(7):e101576. PubMed ID: 24999962
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R.
    PLoS One; 2015 May 09; 10(3):e0120152. PubMed ID: 25790098
    [Abstract] [Full Text] [Related]

  • 30. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
    Wang JW, Wu WH, Huang TC, Wong M, Kwak K, Ozato K, Hung CF, Roden RBS.
    J Virol; 2018 Aug 01; 92(15):. PubMed ID: 29743371
    [Abstract] [Full Text] [Related]

  • 31. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
    Seitz H, Ribeiro-Müller L, Canali E, Bolchi A, Tommasino M, Ottonello S, Müller M.
    Cancer Prev Res (Phila); 2015 Oct 01; 8(10):932-41. PubMed ID: 26170394
    [Abstract] [Full Text] [Related]

  • 32. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.
    Virol J; 2015 Sep 11; 12():140. PubMed ID: 26362430
    [Abstract] [Full Text] [Related]

  • 33. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
    Jagu S, Kwak K, Garcea RL, Roden RB.
    Vaccine; 2010 Jun 17; 28(28):4478-86. PubMed ID: 20434552
    [Abstract] [Full Text] [Related]

  • 34. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
    Yadav R, Zhai L, Kunda NK, Muttil P, Tumban E.
    Viruses; 2021 Jun 10; 13(6):. PubMed ID: 34200586
    [Abstract] [Full Text] [Related]

  • 35. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
    Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.
    Vaccine; 2014 Jun 12; 32(28):3540-7. PubMed ID: 24780250
    [Abstract] [Full Text] [Related]

  • 36. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines.
    Zhang T, Chen X, Liao G, Hu M, Xu J, Xu X.
    J Med Virol; 2020 Dec 12; 92(12):3750-3758. PubMed ID: 31994744
    [Abstract] [Full Text] [Related]

  • 37. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T, Liu H, Chen X, Wang Z, Wang S, Qu C, Zhang J, Xu X.
    Vaccine; 2016 Nov 04; 34(46):5531-5539. PubMed ID: 27729176
    [Abstract] [Full Text] [Related]

  • 38. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
    Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT.
    Clin Vaccine Immunol; 2012 Jul 04; 19(7):1075-82. PubMed ID: 22593236
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
    Schellenbacher C, Roden R, Kirnbauer R.
    J Virol; 2009 Oct 04; 83(19):10085-95. PubMed ID: 19640991
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.